CANbridge Completes $43 Million E Financing for Rare Disease Drugs

CANbridge Pharma completed a $43 million Series E financing that is a follow-on to its $98 million Series D round, announced in February. CANbridge is a Beijing company focused on rare diseases. The company said it would use the proceeds to expand its rare disease pipeline through internal development and external partnerships, advance clinical development of pre-clinical stage assets and launch Hunterase®, a treatment for Hunter syndrome. The E round was led by 3W Fund Management and included new investors Casdin Capital, Summer Capital, SPDBI and Yaly Capital. More details.... Share this with colleagues: // //